drugset
drugset / Trial / NCT07669571

A Phase I Study of NS-079 in Healthy Participants

NCT07669571 ↗

Phase 1 Recruiting 78 enrolled NeuShen Therapeutics
RandomizedSequentialTriple-blindTreatment

Summary

The goal of this clinical trial is evaluate the safety, pharmacokinetics, and pharmacodynamics of NS-079 with its main metabolite (NS-079-M1) in healthy participants. The main questions it aims to answer are: * Is NS-079 safe and tolerable in heathy participants under tested dosing regimen? * What is the pharmacokinectic profile of NS-079 in healthy participants under tested dosing regimen and the effect of paroxetine? Researchers will compare NS-079 to a placebo to see the safety and tolerability when use NS-079.

Timeline

Start
2026-07-30
Primary completion
2027-02-28
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject NS-079 Unknown — —
Subject Paroxetine Small molecule — —

Indications

No indication recorded.